prevalence (incidence), I am not sure. The rates of cancers for the whole screening period (including screen-detected and interval cancers) may shed more light on this. The authors have presented results on cancer rates (screendetected and interval cancer) in the appendix, but how these cancers were defined and how follow-up was handled is not described. Further, result on cancer size for these cancers are not presented. Whether a high detection rate of DCIS and early cancers is better or worse for women is not certain as we know women are overdiagnosed at screening. The ultimate test would be to compare breast cancer mortality rates for the two screening settings.
Additionally, I have some minor concerns: "This time period was selected because we were interested in assessing whether any differences in quality between the two groups existed and/or changed over time after the initiation of the ABCSP." But both periods are after the establishment of the Alberta Breast Cancer Screening Program, and including two time periods complicates your results, message and unless you have a very good reason to include the two periods, I suggest you drop it. "The first screening mammogram for a woman in each study period was defined as the woman's index screen, which marks a "screening episode"", but they could have had screening mammograms before? In the result section you refer to detection rate of invasive cancer in rescreens and initial screens, respectively, but I do not see any result presented for the initial and re screens (only the recommendations). If the populations had different proportions of initial (first time ever) screen and subsequent screens, this may influence your findings.
Why cut off after 30 days of an index screen (for community radiologists)? Sensitivity analysis (ex. Including the same definition in the Screen Test, longer and shorter interval) How was the distribution of follow-up tests (ultrasound, diagnostic mammogram, MRI or biopsy) in time (days, weeks) after index screen?
Seems as the authors has done a sensitivity analysis ("analysis identifies the optimal cut-off as 30 days post index screen with 88% sensitivity and 98% specificity "). Please describe what this analysis is in the method section.
Please describe why you defined screen detected cancers as one appearing within 6 (9) months after index screen. It may be that some of the "interval cancer" are included as screen-detected cancers. You include only positive tests after 30 days of the index screen, I am not sure I understand why you need additional 5 months for a breast cancer diagnosis.
Please add how you estimated abnormal calls, false positives, etc. Did you estimate these measures per round (women), did these measures differ between index mammography and non-index mammography? Did you include DCIS in the detection rates? Please add how you classified stage.
There seem to be a difference in the population that self-referred themselves to the community clinics and the Screen test (more women were node negative in the community setting than with the Screen test, and you explain this by access to care). How did you handle this in the analysis of abnormal calls, false positives, etc. Could your result (difference between detection rate and false positive rates) be explained by differences in the populations (more women with dense breast in the community setting)? Instead of using Rate ratios (seems as the odds ratio) you could consider using rate differences. In table 4 the detection rate of cancers larger than 2 cm are 0.6 and 0.7 in the community setting and 0.9 and 1.2 (all per 1000 screens) in the screen test. These rates seem to be higher in the Screen Test and tumors larger than 2 com may be palpable and should be approximately similar unless there are different populations (and 95% CI may be overlapping). Hence the detection rats may be lower in the community setting due to lower incidence and may also influence PPV (as this measure is dependent on prevalence of disease) although, I agree with the authors that the rate of post What do you refer to by "….corresponidng risk ratios 2.72 (p<0.001) and 2.56 (p<0.001)". risk of cancer? Please add 95% CI in : "The benign biopsy rates (per 1,000 screens) were higher in community clinics during both study period A (8.5 vs. 5.6, RR=1.47, p<0.001) and B (6.7 vs. 4.8, RR=1.35, p=0 .003)". The 95% CI are more informative than p-values.
REVIEWER
Bradley Gray ABIM REVIEW RETURNED 17-Sep-2019
GENERAL COMMENTS
Overall this is an interesting paper with interesting and important outcome measures. The authors worked to to construct these measures in a careful way using claims data. This was impressive.
One small thing, you should not use the term "natural experiment". The term natural experiment is appropriate when there is something that occurs in nature that results in a randomization between treatment and control. An example of this would be a study that looked at the impact of military service on future wages that used a draft lottery as a means for randomization. The authors point out that there are important difference in terms of time between screening between the woman in the treatment and control group. The fact that they looked at all participants (i.e., the whole population) is not comforting. However, access to the whole population would give the authors the ability to match treatment and control group patients through such means as propensity score matching. It is not clear however what patient characteristics are visible to do this matching. At a minimum they could match on age and time between screenings. Even if they did this, you would still have problem around selection related to unobserved factors because there is no real natural experiment here.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 (Dr. Elsebeth Lynge) This is a very interesting study. I have only two comments: 1) the aim in the Introduction is not clearly enough phrased
We revised the last paragraph of the Introduction to read (line 89-91) "The purpose of this study was to assess whether there is systematic variation in the quality of breast cancer screening based on standard performance indicators between the two groups of mammography providers and whether the establishment of the ABCSP improved screen quality."
2) the text is VERY long. I strongly recommend the authors to shorten the text, e.g. aiming for a maximum of 3000 words.
We thank reviewer for this comment. The revised manuscript is now under 3000 words. We cut out materials that were not directly related to the study objectives, and moved Table 1 and Figure 1 to supplementary materials.
Reviewer 2 (Dr. Mette Kalager)
1. My major concern is that although it seems that community based screening has lower quality than Screen Test, it seems as the "true" cancer rates are higher in the population that chooses to go to the Screen Test judged by rates of cancers larger than 2 cm (could be palpable and should be visible on a mammogram; as mammograph detects cancers in the breast and not nodes in the axilla, size is a better measure that node positivity (although the two are associated)). Hence to draw any strong conclusion on the findings are difficult."
We agree that assessing potential differences in cancer rates in the two screening populations is critical to ensure appropriate interpretation of the study findings. To do so, we compared the overall cancer incidence (the combined screen-detected cancer and cancers detected afterwards) in women screened by the two types of providers as well as the overall invasive cancer incidence (the subset of overall cancers that were invasive). Both the overall cancer incidence and the overall invasive cancer incidence are similar across providers, regions and time periods. This analysis was previously shown in Supplementary Table 3 , but to make this important point clearer, we have moved this table into the main manuscript as Table 4 in the revised manuscript. Note to compare the cancer incidence, we used Log binomial models to adjust for age. We also deleted previous Table 4 which we believe, based on this comment, caused confusion rather than clarity.
The higher recall rate (Table 1) , lower screen-cancer detection rate (Table 2) , coupled with a higher post-screen cancer detection rate (Table 3 ) observed in community radiologists as a group is worrisome and likely a quality issue in the interpretation of screen mammograms.
2. The PPV is related to prevalence of breast cancer, but whether false positive rates and the other quality measures are dependent on prevalence (incidence), I am not sure.
We agree that prevalence and incidence are important factors to consider. However: 1) As we pointed out in our response to comment 1, the incidence rates are actually similar in women screened by two types of providers (Table 4 ); and 2) prevalence does not appear in the definition of PPV or false positive rate. PPV = (number of screen-detected cancers)/(number of abnormal recalls). False positive rate = (abnormal recall ratescreen-detected cancer rate) = (number of abnormal callsnumber of screen-detected cancers)/number of screen mammograms.
Thus, both quantities related to the number of abnormal calls that a radiologist makes as well as screen-detected cancer among these abnormal calls. Although prevalence is somewhat related to screen-detected cancer, they are not the same quantity, unless screen mammography has 100% sensitivity. The differences in PPV and false positive rates as shown in our manuscript mainly come from the number of abnormal calls, while a smaller contribution is from the screen-detected cancer among these abnormal calls.
3. The rates of cancers for the whole screening period (including screen-detected and interval cancers) may shed more light on this. The authors have presented results on cancer rates (screen-detected and interval cancer) in the appendix, but how these cancers were defined and how follow-up was handled is not described. Further, result on cancer size for these cancers are not presented.
The definition of screen-detected and interval cancer (a.k.a. post-screen cancer) was defined in Lines 136-139 of our original submission. In the revision, due to the space limitations, we moved the definitions and derivations of key quantities including screen-detected cancer and post-screen invasive cancer to the Supplementary Materials. We listed them here for your convenience. Please note that we published the validation of the method we used to identify the optimal time frame that differentiates between screen-detected and non-screen detected cancer using the very same data set as that were analyzed in this manuscript 1 .
Definitions and derivations of key quantities using administrative data (based on validated algorithm 1 and definition used in the Canadian guideline 2 ) Abnormal recall: An index screen mammography procedure followed by any breast-related procedure (mammogram, ultrasound, MRI, biopsy etc.) in the next 30 days, or an index screen that associated with diagnosis of cancer within 6 months (9 months in one remote region in Alberta). Note, this algorithm classifies abnormal/normal with a sensitivity of 88% and specificity of 99%. The overall accuracy is 98%. (Unpublished data, using methods described in a previous publication 1 ) Normal screen: An index screen that is not classified as abnormal. Screen-detected cancer: Breast cancer diagnosed per Alberta cancer registry record within 6 months (9 months in one remote region) of an index screen. 1 False positive: Abnormal recall that did not result in a screen-detected cancer, i.e. abnormal recall minus screen-detected cancer. Benign biopsy: Biopsy procedure following an abnormal recall that did not result in a screendetected cancer.
Post-screen invasive cancer: An invasive non-screen detected cancer diagnosed after a normal screen but before a subsequent screen mammogram.
Positive Predictive Value (PPV):
The percentage of cancer detected among abnormal recalls, i.e. Number of screen-detected cancer/Number of abnormal recalls X 100%.
Overall cancer: Breast cancer diagnosed per Alberta cancer registry record within a pre-specified period of an index screen.
We used the standard methodology to handle follow-up when post-screen invasive cancer rate is estimated 2 . Specifically, the follow-up time for each woman with a normal screen result is calculated from her index screen until either her subsequent screen, a diagnosis of breast cancer, or the pre-specified time interval of interest, whichever is the earliest.
The main points of our manuscript are to compare the quality of breast cancer screening services using the standard performance indicators between the two types of providers and to investigate whether screen quality improves over time with the establishment of Alberta Breast Cancer Screening Program. To focus on our main objectives, in this revision we removed We agree that mortality is the ultimate indicator and an important point to consider. However, the purpose of this manuscript is to compare the quality of the breast cancer screening services utilizing standard performance indicators. It is a lower invasive cancer detection rate, combined with higher rates of false positives, benign biopsy and post-screen cancer in the same population that are concerning, and worth the attention of the medical community and public (Tables 2, 3 and 4 in the revised manuscript).
Minor concerns:
5. "This time period was selected because we were interested in assessing whether any differences in quality between the two groups existed and/or changed over time after the initiation of the ABCSP." But both periods are after the establishment of the Alberta Breast Cancer Screening Program, and including two time periods complicates your results, message and unless you have a very good reason to include the two periods, I suggest you drop it
We conducted a cross-sectional study in two consecutive periods; each covers a two-year period. Our reasons for doing this are: 1) The Canadian prevention task force recommended breast cancer screen every two years to women between 50-69 years of age. A two-year cross-sectional period captures women who adhere to the guideline. 2) The Alberta Breast Cancer Screening Program officially launched in 2006 when the private database maintained by radiologists working in the community clinics was fully linked with the database maintained by the provincial-run Screen Test. Theoretically, there is only a single program screening operating in Alberta. It is thus of interest to investigate whether or not the establishment of this overarching program improves the quality of screen in the community clinics.
As we observed from the results, unfortunately there is not much quality improvement from the 1 st period to the 2 nd period in the community clinics, emphasizing the need and importance of regulatory body's oversight in ensuring program efficiency.
6. "The first screening mammogram for a woman in each study period was defined as the woman's index screen, which marks a "screening episode"", but they could have had screening mammograms before? In the result section you refer to detection rate of invasive cancer in rescreens and initial screens, respectively, but I do not see any result presented for the initial and re screens (only the recommendations). If the populations had different proportions of initial (first time ever) screen and subsequent screens, this may influence your findings.
Unfortunately, it is a limitation of the cross-sectional administrative data: there is no way to identify whether the index screen is an initial screen or a re-screen. We could not stratify the quality indicators by initial screen. We recognize this limitation and ran an additional sensitivity analysis in the subset of women whose index screen results were normal in study period A and who had their subsequent screening between 18 and 30 months after her index screen. The results are presented in supplemental tables 3 and 4 and discussed in lines 274-279 in the revised manuscript: "… sensitivity analysis conducted for women who had a normal index screen in study period A and were subsequent screened between 18 to 30 months. The same pattern of differences emerged: community clinics had a lower cancer detection rate (2.4 vs. 4 .0 per 1,000 screens) and a higher abnormal recall rate (6.6% vs. 2.5%) when compared to Screen Test in the subsequent screening ( Supplementary Table 3 ). Additionally, the low cancer detection rate was attributed to the lower invasive cancer rate ( Supplementary Table 4 )."
7. Why cut off after 30 days of an index screen (for community radiologists)? Sensitivity analysis (ex. Including the same definition in the Screen Test, longer and shorter interval) How was the distribution of follow-up tests (ultrasound, diagnostic mammogram, MRI or biopsy) in time (days, weeks) after index screen?
This is a good point. We have developed and validated an algorithm using both administrative billing data which don't have procedure results and private data collected by Alberta radiologists that have results. The details can be found in our previous publication "Using administrative data to estimate time to breast cancer diagnosis and percent of screen-detected breast cancers -a validation study in Alberta, Canada. European Journal of Cancer Care. 2015;24(3):367-375" (reference 17 in the revised manuscript). In that study, we found 6-month to be the optimal interval to accurately classify screen-detected cancer in all but one health region of Alberta. The distribution of the follow-up tests were published in "Shen Y, et. al. Canadian Journal of Public Health. 2018; 108(5-6) :539-545." (reference 23 in the revised manuscript).
8. Seems as the authors has done a sensitivity analysis ("analysis identifies the optimal cut-off as 30 days post index screen with 88% sensitivity and 98% specificity "). Please describe what this analysis is in the method section.
Please see response to Comment 7. Due to space limitations, we do not include the details of the sensitivity analysis in the present manuscript as we believe they are only indirectly related to the current manuscript and we have provided references. Briefly, various timeintervals were systematically examined to determine the relevance of a sequence of tests, including abnormal/normal screening results. We used a ROC curve, misclassification rate and cumulative density function to choose the optimal tme interval for identifying screen-detected cancer. We demonstrated that routinely collected administrative physician claims data can be reliably used to answer specific research questions in breast cancer diagnostic care.
9. Please describe why you defined screen detected cancers as one appearing within 6 (9) months after index screen. It may be that some of the "interval cancer" are included as screendetected cancers. You include only positive tests after 30 days of the index screen, I am not sure I understand why you need additional 5 months for a breast cancer diagnosis.
Please see our response to comment 7.
10. Please add how you estimated abnormal calls, false positives, etc. Did you estimate these measures per round (women), did these measures differ between index mammography and non-index mammography?
Please see our response to comment 2 for the estimation of key quality measures. We estimated these measures on one index screen and its screen episode per women during each study period of 2-years. We did not estimate these measures per round. As we have four years of data, the number of screens can range from 1 to 5 for the women included in our study. We feel the index screen/screen episode per women per study period approach is most appropriate.
Did you include DCIS in the detection rates?
Please add how you classified stage. Table 2 reported screen-detected cancer rate stratified by invasive, DCIS and total (sum of invasive and DCIS cancer). Cancer stage (in Table 4 original submission, removed in the revision) is from Alberta cancer registry record, which uses American Joint Committee on Cancer (AJCC) staging system using TNM.
12. There seem to be a difference in the population that self-referred themselves to the community clinics and the Screen test (more women were node negative in the community setting than with the Screen test, and you explain this by access to care). How did you handle this in the analysis of abnormal calls, false positives, etc.
Please see response to comment 1. Supplementary Table 2 shows age distributions are virtually the same between the two groups of women. Physical clinics run by both Screen Test and community radiologists operate in Edmonton and Calgary, the two metro cities in Alberta (lines 77-83). Women residing in either city have no access to care issues, unlike women live in remote areas who are served by Screen Test mobile units. Women are also unaware of the fact that two distinct systems operate under the same screening program and urban residing women freely choose any radiology clinic for breast cancer screening. To mitigate potential bias due to access to care, all our analyses were stratified by regions. We emphasize the comparison of providers within the two metro cities.
13. Could your result (difference between detection rate and false positive rates) be explained by differences in the populations (more women with dense breast in the community setting)? Instead of using Rate ratios (seems as the odds ratio) you could consider using rate differences.
In table 4 the detection rate of cancers larger than 2 cm are 0.6 and 0.7 in the community setting and 0.9 and 1.2 (all per 1000 screens) in the screen test. These rates seem to be higher in the Screen Test and tumors larger than 2 com may be palpable and should be approximately similar unless there are different populations (and 95% CI may be overlapping). Hence the detection rats may be lower in the community setting due to lower incidence and may also influence PPV (as this measure is dependent on prevalence of disease) although, I agree with the authors that the rate of post
We only had access to administrative data which does not have breast density data in it. We use age as an approximate measure for breast density. The two groups of women have similar age distribution across regions (Supplementary Table 1 ). As we explained in response to comment 12, in Edmonton and Calgary, radiological clinics are managed by either Screen Test or community radiologists. Neither screening eligible women nor the majority of family physicians in the provinces are aware that there are two distinct systems offering screening service. Women freely choose any radiology clinic for breast cancer screening, thus mimicking a natural experiment. The likelihood of systematic difference in characteristics, e.g. breast density, is therefore, low between women serviced by the two types of providers.
As we noted in our response to comment 1, there are systematic differences in screening intervals. The average rescreen intervals are shorter for women received her index screen in the community clinics than those screened in Screen Test (Supplementary Figure 2) . This may explain the slightly higher (but not statistically significant) cancer rate of larger tumors by Screen Test for women from Edmonton and Calgary (Table 4 in original submission, removed in the revision).
Rate ratio is estimated using an age-adjusted regression model. We are unaware of regression methods for rate difference in which age can be adjusted. If we carry out both tests ignoring age, then the estimated rate ratio and rate difference would give similar p-values. This is because both tests would be based on the same contingency table and the two null hypotheses, i.e. rate difference = 0 and ratio =1, are equivalent.
1. One small thing, you should not use the term "natural experiment". The term natural experiment is appropriate when there is something that occurs in nature that results in a randomization between treatment and control. An example of this would be a study that looked at the impact of military service on future wages that used a draft lottery as a means for randomization.
Thank you for your comment about natural experiment. While we agree with your definition, we also believe it is appropriate to expand this definition to apply to a comparison of 'treatment 1' vs 'treatment 2' (rather than treatment vs control). In our case, screening in the community could be considered 'treatment 1' and screening by Screen Test 'treatment 2'. Although women are not strictly randomized, they arbitrarily choose to receive screening at either a community-based clinic or a ScreenTest clinic in a way that is independent of their disease state. The arbitrary selection of screening provider is a situation similar to a natural experiment (but not at 1:1 ratio) for women live in Edmonton and Calgary. This is because unknown to women and their family physicians radiological clinics in these two cities are managed by either Screen Test or community radiologists, two different types of service providers as we describe. Women freely choose any radiology clinic for breast cancer screening. It is in this sense that this setting conceptually mimics a single blind randomized experiment. Due to the limitation of the administrative data, however, we could not compare the characteristics of women other than their age, which were shown to be remarkable similar ( Supplementary Table 1 ).
We revised our manuscript to read (line 262-268) "The main advantages of this study are that the two ways to access breast cancer screening in Alberta provide a natural experiment to assess differences in quality of screening between the two breast cancer screening models. Neither screening eligible women nor the majority of family physicians in the provinces are aware that there are two distinct systems offering screening service. Women living in Edmonton and Calgary choose to receive screening at either a community-based clinic or a Screen Test clinic. Their choice is independent of their disease state. The arbitrary selection of screening provider conceptually mimics a single blind randomized experiment."
2. The authors point out that there are important difference in terms of time between screening between the woman in the treatment and control group. The fact that they looked at all participants (i.e., the whole population) is not comforting. However, access to the whole population would give the authors the ability to match treatment and control group patients through such means as propensity score matching. It is not clear however, what patient characteristics are visible to do this matching. At a minimum, they could match on age and time between screenings. Even if they did this, you would still have problem around selection related to unobserved factors because there is no real natural experiment here.
We agree with the reviewer that time between screenings should be comparable to ensure a fair comparison. Thus we have conducted sensitivity analyses examining the same set of performance indicators in subsequent screening where the screen interval is between 18 and 30 months. In line 274-279 revised manuscript, "We performed sensitivity analysis for women who had a normal index screen in study period A and subsequently screened between 18 to 30 months. The same pattern of differences emerged: community clinics had a lower cancer detection rate (2.4 vs. 4 .0 per 1,000 screens) and a higher abnormal recall rate (6.6% vs. 2.5%) when compared to Screen Test in the subsequent screening ( Supplementary Table 3 ). Additionally, the low cancer detection rate was attributed to the lower invasive cancer rate ( Supplementary Table 4 )."
In this sensitivity analysis, women had similar screen-intervals and the analyses were adjusted for age. The results were similar to the main analyses shown in Tables 2 and 3 .
We have sliced the data in a number of different ways, including regions and time period. Analyses were performed with and without adjusting for age, and a number of sensitivity analyses were also performed. All analyses consistently showed superiority of quality in Screen Test in every standard performance indicators,
